FDA Warning Letter Renews Concerns About Barring Inspection Photos
This article was originally published in The Rose Sheet
Executive Summary
An FDA warning letter issued in August to OTC drug manufacturer Homeolab has revived discussion about companies' options when it comes to investigator photographs during facility inspections, prompting fresh insight from industry attorneys on the issue's legal underpinning and existing case law.
You may also be interested in...
FDA Inspection Photography: Pick Your Battles, Cover Your Bases
Firms concerned about trade secrets or other confidential business information have options for resisting photography in the context of FDA inspections, but they should be prepared to be labeled "uncooperative" and could draw a warning letter identifying their offerings as adulterated.
FDA Inspection Photography: Pick Your Battles, Cover Your Bases
Firms concerned about trade secrets or other confidential business information have options for resisting photography in the context of FDA inspections, but they should be prepared to be labeled "uncooperative" and could draw a warning letter identifying their offerings as adulterated.
GMP Problems Stop Canadian Firms’ Topical OTC, Homeopathic Imports
Homeolab USA’s and Cellex-C’s imports were stopped earlier in 2017 following GMP inspections at their facilities, and FDA warns that approvals for marketing of additional products in the US could be withheld until each firm is GMP-complaint. Homeolab trips up by trying to prevent FDA photography inside plant.